Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021
Authors' conclusion
Rheumatoid arthritis mortality has decreased globally over the past three decades. Global age-standardised prevalence rate and YLDs have increased over the same period, and the number of cases is projected to continue to increase to the year 2050.
Study context
- Population
- RA in 204 countries and territories, 1990 to 202098 prevalence and 25 incidence studies
- Outcome
- RA prevalence, deaths and DALYs by age, sex, year and location, with forecasted prevalence to 2050
- Follow-up
- 2020
Methodological detailsBayesian meta-regression, Cause of Death Ensemble model (CODEm) mortality modelling, forecast to 2050 by logistic regression with Socio-Demographic Index
- Bayesian meta-regression
- CODEm mortality modelling
- Forecast to 2050 by logistic regression with Socio-Demographic Index
Main finding
As reported in the abstract
RA burden, global
- People with RA worldwide, million
- 17.6 (95% UI 15.8-20.3)
- Age-standardised global prevalence rate, cases per 100 000 (186.8-241.1)
- 208.8
- Increase in age-standardised prevalence since 1990, % (12.7-15.4)
- 14.1%
- Age-standardised female-to-male prevalence ratio (2.40-2.47)
- 2.45
- Age-standardised death rate per 100 000 (0.41-0.54)
- 0.47
- Global deaths (33 500-44 000)
- 38 300
- Decrease in age-standardised death rate 1990 to 2020, % (17.5-29.3)
- 23.8%
- DALY count (2 320 000-3 860 000)
- 3 060 000
- Age-standardised DALY rate per 100 000 (27.6-45.9)
- 36.4
- Years lived with disability (YLDs) share of DALYs (68.3-81.0)
- 76.4%
Further findings
Smoking risk attribution for RA DALYs · 2020
- Attributable to smoking
- 7.1% (95% UI 3.6-10.3)
Forecast people living with RA worldwide · 2050
- Individuals, million
- 31.7 (95% UI 25.8-39.0)
- Forecast
Original publication
Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. Published 25 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →